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Background: Recent studies investigating the use of optical coherence tomography (OCT)
in multiple sclerosis (MS) patients have resulted in wide-ranging and often contradictory
outcomes. This is mainly due to the complex etiology and heterogeneity of MS, physio-
logical variations in the retinal nerve fiber layer (RNFL) and/or total macular volume (TMV),
and limitations in methodology. It remains to be discovered whether any retinal changes in
MS develop continuously or in a stepwise fashion, and whether these changes occur in all
or a subset of patients. High-resolution spectral domain-OCT devices (SD-OCT) would be
required to detect subtle retinal changes and longitudinal studies would have to be carried
out to investigate retinal changes over time. In addition, if the hypothesis is correct, then
retinal and global brain tissue changes should be detected in a substantial majority of MS
patients and detection should be possible with a high degree of disease activity and/or
long disease course.
Methodology: In order to address the factors above, 37 MS patients (relapsing–remitting,
n=27; secondary progressive, n= 10) were examined prospectively on two occasions
with a median interval of 22.4±0.5 months [range 19–27]. SD-OCT was utilized with the
Spectralis 3.5 mm circle scan protocol (with locked reference images and eye-tracking
mode). None of the patients had optic neuritis 12 months prior to study entry or during
the observation period.
Principal Findings: The initial TMV pattern differed between study participants, but
remained relatively unchanged over the 2-year observation period despite high disease
activity or long disease course. The TMV correlated well with the RNFL.
Conclusion: The significance of differences in TMV (and RNFL) between study partici-
pants remains unclear. Until these differences have been explored further, OCT data in MS
patients should be interpreted with caution.
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INTRODUCTION
It has recently been described that the retinal nerve fiber layer
(RNFL) thickness in multiple sclerosis (MS) patients can be reli-
ably visualized by optical coherence tomography (OCT), and
that RNFL reduction correlates to diffuse axonal and/or neuronal
degeneration throughout the CNS. This is regardless of whether
the eyes have previously been affected by optic neuritis (ON). In
addition to the ganglion cell and RNFLs, the total macular volume
(TMV) has also been described as a reliable variable in the use of
OCT in MS patients.
Loss of TMV was described as an additional neuromarker
for the degree of global degeneration of myelin, axons, oligo-
dendrocytes, and astrocytes throughout the CNS of MS patients.
Furthermore, changes in TMV were suggested to be more reliable
at detecting global neurodegeneration than the observed decrease
in the RNFL thickness (1–3).
However, some crucial questions still remain:
(1) How and why would 2.5 million axons of both optic nerves
be representative of billions of axons within the entire CNS?
(2) Is there a continuous, degenerative process in the entire CNS
taking place in every MS patient, and if so, does it proceed
at the same pace in all CNS areas simultaneously? How does
this hypothesis apply to those MS patients who follow a clear
relapsing–remitting disease course with only few relapses and
who are not disabled over decades (4)?
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(3) The term “neurodegeneration,” when applied to MS, needs
a clear definition. What is meant by primary or secondary
degeneration of neurons? Neuropathologists still classify MS
as a white matter disease, although it has been established for
more than a century that myelin, oligodendrocytes, astroglia,
and axons are damaged in MS lesions, and that white and gray
matter are both affected (5). It seems that, in recent years,
there has been significant distortion in semantics, which has
impeded uniformity between studies (ranging from the use
of axonal damage over degeneration of axons, or moving from
neuronal degeneration to “neurodegeneration”). In any case,
the term “neurodegeneration” implies a primary degenerative
process of neurons, and thus should be avoided as long as
direct scientific evidence is lacking.
(4) Can the hypothesized retinal changes described above be
detected with every OCT device, or is there a minimal techni-
cal standard required, as the latest high-resolution SD-OCT is
currently assumed to be the golden standard. (1, 6–8)?
(5) Can very subtle changes, described above, be separated from
gross changes caused by ON or even physiological variations
(6–8)?
(6) Are OCT devices really suitable for the detection and monitor-
ing of expected, subtle RNFL- and TMV changes as there is yet
no reliable and normative database available for this specific
indication (6, 8).
Most importantly, the existing literature and prospective
reports utilizing SD-OCT in MS studies must be interpreted
with caution, as even physiological variations of the RNFL or
TMV (in addition to the hypothesized subtle retinal changes of
<2–4µm/year) were found to exceed the detection-threshold of
high-resolution spectral domain-OCT (SD-OCT) devices (8). To
date, most of the OCT studies were performed with conventional
time-domain OCT, which has proved to be far inferior to high-
resolution SD-OCT, lacking the ability to measure changes in
RNFLT of identical retinal locations over time (9).
To address the factors described and avoid methodological limi-
tations, we utilized a high-resolution SD-OCT and a well-classified
cohort of 27 RRMS and 10 SPMS patients with partly intense dis-
ease activity and high relapse-rates over a prolonged observation
period of approximately 22.4± 0.5 months.
MATERIALS AND METHODS
PARTICIPANTS
This study was approved by the local Ethics Committee (Com-
mission of Medical Ethics of Vienna; Ethic Approval/Registration
Number: EK-08-028-0308 and Ethical Commission of the Med-
ical University of Vienna; Ethic Approval/Registration Num-
ber: 414/2008). Informed written consent was obtained from all
patients and volunteers before study entry.
We recently reported both the demographic and clinical data,
the RNFL baseline characteristics of a total of 59 MS (42 RRMS, 17
SPMS) patients, and the follow-up RNFL characteristics of those
37 MS patients (27 RRMS, 10 SPMS) who were willing to par-
ticipate further (6, 8). The TMV was determined in each case
in the same session as the RNFL. Patients were encouraged to
drink sufficiently (1–2 L) 1–2 h before each session to guarantee
hydration.
In each case, the diagnosis of MS was based on a combina-
tion of clinical course, MRI, cerebrospinal fluid (CSF) analysis,
and the exclusion of other disorders or diseases (10–12). Oligo-
clonal bands were found in the CSF samples of all MS patients.
Patients with other diseases that reduce RNFL thickness such as
glaucoma, anterior ischemic optic neuropathy, high myopia, and
congenital abnormalities of the optic nerves were excluded from
the study.
Baseline clinical neurological examinations, visual evoked
potentials (VEP), and ophthalmologic examinations were per-
formed within 7 days. None of the patients had a history of ON
within 12 months prior to the onset of the study. A summary of
detailed demographic and clinical data for each patient is given in
Table 1 (8).
HIGH-RESOLUTION SPECTRAL DOMAIN-OCT
We used a high-resolution SD-OCT, which combines OCT tech-
nology with a confocal scanning laser ophthalmoscope (Heidel-
berg Engineering, Heidelberg, Germany, Spectralis software ver-
sion 4.0.3.0, Eye Explorer Software 1.6.1.0, in addition to Eye
Explorer software version 1.6.2.0 due to changes by the man-
ufacturer during the follow-up period). A special eye-tracking
mode (TrueTrac™) combined with a high scanning speed (40,000
A-scans/s) with an axial resolution of 7µm and a transversal res-
olution of 14µm allows for the reduction of artifacts due to eye
movement. Each macular OCT scan is registered and locked to a
reference infrared image. In addition, an automatic real-time aver-
aging mode (ART mode) allows for adjustment of the recorded
frames to obtain averaged B-scans, which enhances image quality
by optimizing the signal-to-noise ratio. The eye tracker and auto-
matic real-time averaging modes of the Spectralis SD-OCT system
were used throughout the study. For follow-up scanning, the
OCT software could identify previous scan locations and “guide”
the OCT laser beam to scan the same location repeatedly. All
automated measurements of macular thickness and volume were
performed through dilated pupils with a high-resolution macular
scan protocol allowing for a more detailed differentiation of retinal
layers. (The TMV compounds of inner limiting membrane, nerve
fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear
layer, outer plexiform layer, outer nuclear layer, external limiting
membrane, photoreceptor layer, and retinal pigment epithelium.)
All macular scans were performed by one skilled and trained
observer (NS) within one session and repeated if necessary, until a
high-quality macular scan was achieved for use in further analysis.
Final analysis was only performed on scans without segmenta-
tion errors and no manual correction was performed in any case.
The observer had no knowledge of any clinical data or the spe-
cific baseline data. The SD-OCT imaging protocol comprised 49
B-scans per volume scan of 20°× 20°, and each scan was averaged
with 9 frames per B-scan. Topographic macular surface maps were
constructed automatically by the OCT software and displayed with
numeric averages of the mean thickness for each of the nine map
sectors (F, foveal; TI, inner temporal; TO, outer temporal; II, inner
inferior; IO, outer inferior; NI, inner nasal; NO, outer nasal; SI,
inner superior; SO, outer superior) within three concentric regions
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Table 1 | Summary of demographic and clinical data.
No MS
subtype
Sex Age at
onset
Before first OCT examination Follow-up
Therapy Relapses* ON Age at
baseline
Age at
follow-up
Relapses* Therapy
Right Left
1 RRMS F 34.5 MITOX, GLAT, IFN(b), IFN(a) 7 0 0 40.5 42.25 3 Natalizumab
2 RRMS F 18.5 IFN(a), IFN(b) 4 0 0 23.5 25.25 3 Natalizumab
3 RRMS F 36.0 MITOX1, IFN(a) 7 0 0 42.0 43.5 2 Natalizumab
4 RRMS F 31.5 None 3 0 0 38.0 40.25 0 None
5 RRMS M 40.0 IFN(a) 3 0 0 45.5 47.5 0 IFN(a)2; none
6 RRMS F 28.5 IFN(b) 3 0 0 39.0 40.75 2 IFN(b), natalizumab3
7 RRMS F 43.0 GLAT, IFN(b), none4 4 0 0 48.0 49.75 3 None, natalizumab
8 RRMS F 40.0 None 2 0 0 42.25 44.0 0 None
9 RRMS M 24.0 None 2 0 0 25.0 26.5 0 None
10 RRMS F 18.0 GLAT, none5 2 0 0 19.75 21.5 1 None
11 RRMS F 29.75 IFN(a)6, none 4 0 0 36.0 37.5 1 None
12 RRMS M 31.0 IFN(b) 2 0 0 33.25 35.0 1 IFN(b)
13 RRMS M 51.0 IFN(b) 2 0 0 52.0 54.75 0 IFN(b)
14 RRMS F 23.75 None 2 0 0 27.0 28.5 0 None7
15 RRMS M 27.5 GLAT 4 0 0 39.0 40.75 0 GLAT
16 RRMS F 30.0 IFN(b)8, none 4 0 0 46.0 48.5 0 None
17 RRMS M 39.0 IFN(c) 4 0 0 45.0 47.25 1 IFN(c)
18 RRMS F 20.0 IFN(a)9, none 2 0 0 23.0 25.25 2 None
19 RRMS F 16.0 GLAT 4 0 0 61.0 63.25 0 GLAT
20 RRMS F 20.5 IFN(b)10, none 5 0 0 28.0 30.25 1 None
21 RRMS F 26.0 IFN(a), IFN(b), MITOX11, none 9 1 1 32.0 34.0 0 None
22 RRMS F 17.75 IFN(a), IFN(b) 6 1 3 19.75 21.75 1 IFN(b)12, natalizumab
23 RRMS F 31.0 IFN(a), IFN(b) 4 1 0 36.0 38.25 0 IFN(b)
24 RRMS F 20.0 IFN(b) 8 1 1 47.5 49.0 1 IFN(b)
25 RRMS M 22.5 GLAT, IFN(a), IFN(b), natalizumab 10 0 1 42.5 44.0 0 Natalizumab
26 RRMS F 20.0 IFN(a) 3 0 4 41.0 42.5 0 IFN(a)
27 RRMS M 31.0 GLAT13, none 2 0 1 33.0 35.25 0 None
28 SPMS M 40.0 GLAT, MITOX14, none 3 0 0 46.5 48.5 0 None
29 SPMS F 13.0 IFN(b), MITOX15, none 5 0 0 27.0 29.25 2 None
30 SPMS F 38.0 GLAT, none 3 0 0 45.0 47.25 0 None
31 SPMS F 33.5 None 3 0 0 56.0 58.25 0 None
32 SPMS M 28.0 IFN(a), IFN(b) 11 0 0 47.25 49.0 1 IFN(b)
33 SPMS M 25.0 IFN(c), GLAT, IFN(a), IFN(b) 10 1 1 47.5 49.75 1 IFN(b)
34 SPMS M 22.0 IFN(b) 5 1 0 30.5 32.25 2 IFN(b)16, none
35 SPMS F 16.0 IFN(a), MITOX17, none 6 0 2 44.25 46.5 2 None
36 SPMS F 50.0 GLAT 4 0 2 53.5 55.75 2 GLAT
37 SPMS M 29.0 IFN(b) 3 0 1 52.0 53.75 0 IFN(b)
ON, optic neuritis; *, relapses treated with high dose steroid pulse therapy; no included patient had an ON within 12 months prior to the beginning of the study;
GLAT, glatiramer-acetate 20 mg subcutaneous once daily; MITOX, mitoxantrone; IFN(a), interferon beta 1a intramuscularly once/week; IFN(b), interferon beta 1a
(44µg) subcutaneous trice/week; IFN(c), interferon beta 1b (250µg) subcutaneous alternate day; 1, discontinued (48 mg mitoxantrone/m2 body surface); none, nei-
ther specific immunomodulatory or immunosuppressive therapy, drug holiday; 2, drug withdrawal 9 months after first OCT examination; 3, start 7 months before
second OCT examination; 4, drug withdrawal 12 months before first OCT examination; 5, drug withdrawal 6 months before first OCT examination; 6, drug withdrawal
20 months before first OCT examination; 7, strict vegan diet caused vitamin B12 and folate deficiency; 8, high titers of anti-interferon autoantibodies, drug withdrawal
14 months before first OCT examination; 9, drug withdrawal 25 months before first OCT examination; 10, drug withdrawal 8 months before first OCT examination;
11, mitoxantrone cumulative dose 96 mg/m2 body surface, drug withdrawal 10 months before first OCT examination; 12, change to natalizumab 2 months after first
OCT examination; 13, drug withdrawal 6 months before first OCT examination; 14, mitoxantrone cumulative dose 92 mg/m2 body surface, drug withdrawal 10 months
before first OCT examination; 15, mitoxantrone cumulative dose 92 mg/m2 body surface, drug withdrawal 26 months before first OCT examination; 16, drug withdrawal
5 months after first OCT examination 17, mitoxantrone cumulative dose 108 mg/m2 body surface, drug withdrawal 27 months before first OCT examination.Table 1
was already published in Ref. (7).
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of 1, 3, and 6 mm diameter, respectively, as defined by the Early
Treatment Diabetic Retinopathy Study (ETDRS).
VISUAL FUNCTION TESTING, VISUAL FIELD ANALYSIS, VISUAL EVOKED
POTENTIALS
Visual function testing, visual field analysis, and VEP have been
described previously (6, 7).
STATISTICS
The statistics used in this study has been described previously
(6–8).
RESULTS
The results of our study performed with the high-resolution SD-
OCT can be summarized briefly as follows: over a median obser-
vation period of 22.4± 0.5 months (range from 19 to 27 months),
the TMV measurements of each MS patient were unchanged
compared to baseline (Figure 1). The minimal positive/negative
changes seen in some follow-up scans were within the interses-
sion/observer variation (Figures 1 and 2) (3, 6–8). Mean TMV
values were found highest in RRMS patients without ON. Mean
TMV values were found lower in RRMS with ON and in SPMS
with and without ON (Figure 2). The visual and contrast acu-
ity and sensitivity tests (ETDRS, Sloan and Pelli-Robson-charts),
the color vision test (Lanthony D-15), the Humphrey visual field
analysis, and the VEP also showed no changes compared to
baseline values (8). Again, neither age, disease duration, or MS
subtype was found to correlate with TMV changes, but TMV
values were found moderately correlated to the RNFL values
(Figure 3).
DISCUSSION
A number of cross-sectional OCT-trials have demonstrated a
decrease in the RNFLT of patients with MS compared with healthy
controls, which was more prominent in progressive disease than
in the RR course (13–15). This has led to the assumption that
the decrease of RNFLT may reflect “neurodegeneration,” cerebral
atrophy, and a progressive disease course (13, 15). This has yet to
be confirmed in prospective, controlled longitudinal studies (16).
Loss of TMV has been considered as an even more reliable marker
for “neurodegeneration” (2).
In this long-term follow-up trial, we were not able to detect any
significant reduction of TMV in MS patients over an observation
period of 22.4± 0.5 months [range 19–27]. All TMV variations
(± compared to baseline) were within the intersession and mea-
surement variability of the high-resolution SD-OCT device used
in the study (17). The results of our study reflect the negative data
FIGURE 1 | GlobalTMV changes between baseline and follow-up
examination. (A), left eye; (B), right eye; 1–37, patient 1–37 (seeTable 1 for
demographic and clinical data); white squares, RRMS without ON
(baseline follow-up); black squares, RRMS with ON (baseline
follow-up); white triangles, SPMS without ON (baseline follow-up); black
triangles, SPMS with ON (baseline follow-up); black bars, means.
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FIGURE 2 | Variation of globalTMV measurements. (A,B) Variation of RNFL
measurements between baseline and follow-up examination in relation to the
total relapses (without ON) before study entry. (C,D) Variation of RNFL
measurements between baseline and follow-up examination in relation to the
relapses (without ON) during the observation period. (A) Left eye; (B) right
eye; (C) left eye; (D) right eye; white squares, RRMS without ON; black
squares, RRMS with ON; white triangles, SPMS without ON; black triangles,
SPMS with ON.
of a follow-up investigation on RNFLT in the same cohort of MS
patients (6, 8). This is not surprising as axons from the optic nerve
originate from receptor ganglion cells of the macula. It should
be stated that studies where RNFLT and TMV do not correlate
strictly should be interpreted with caution (3). It is likely that if
both parameters change (increase or decrease), then they change
simultaneously. Which of the two parameters is considered to be
more reliable in visualizing the suspected focal (or hypothesized
diffuse progressive) subtle changes is still a matter of debate (3)
and cannot be answered reliably. To date, the majority of OCT
studies were performed to analyze the RNFLT in MS patients. A
MEDLINE search reveals 125 results for “MS AND RNFL” but
only 6 results for for “MS AND TMV,” e.g., Ref. (1–3, 6–8, 12, 16,
18–20).
Nevertheless, (1) large normative databases and (2) longitu-
dinal studies performed with high-resolution SD-OCT devices,
large patient numbers and controls (at least several hundred), and
long observation periods over several years (>5 years) are lacking.
Meta-analyses are limited as (1) the measurements of individual
devices are not interchangeable and comparable (9), (2) inclusion
criteria of the patients are not clear, or (3) “affected eyes” were sep-
arated from their “unaffected fellow eyes,” hence the case numbers
being doubled (20). Most importantly, physiological variations of
the RNFLT or TMV were found to exceed the detection-threshold
of SD-OCT devices and the hypothesized subtle retinal changes of
<2–4µm/year (7).
Both the current study and our previous studies (6, 8) give rise
to a more critical evaluation of OCT as an efficient monitoring
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FIGURE 3 |TMV over time. (A,B) Changes of the TMV over time. (A) Left
eye – weak correlation of global TMV changes over time. y =8.5−0.001×
x [correlation coefficient=−0.4; R2 =18.7%; standard error of estimate=
0.4]. (B) Right eye – weak correlation of global TMV changes over time.
y =8.5−0.001× x [correlation coefficient=−0.4; R2 =14.4%; standard
error of estimate= 0.4]. (C,D) Correlations between TMV and the RNFL.
(C) Left eye – moderately strong relationship between TMV and RNFL.
y =6.4+0.02× x [correlation coefficient=0.7; R2 =47.9%; standard error
of estimate=0.3]. (D) Right eye – moderately strong relationship between
TMV and RNFL. y =6.4+0.02× x [correlation coefficient=0.7;
R2 =48.5%; standard error of estimate=0.3]. (A) Left eye; (B) right eye;
(C) left eye; (D), right eye; white squares, RRMS without ON; black
squares, RRMS with ON; white triangles, SPMS without ON; black
triangles, SPMS with ON.
instrument for MS disease progression, and thus any interpreta-
tion of therapeutic studies must proceed with the utmost caution
(1–3, 6–8, 12, 18–21).
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